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In this study we aim to evaluate the prognostic and predictive value of cetuximab-mediated ADCC and to analyse its correlation with PFS) and OS) in a cohort of 41 mCRC patients treated with cetuximab-based therapy. Moreover we aim to investigate the association between the SNPs inside FCGR2A and FCGR3A genes and the effect of cetuximab treatment in this mCRC patients' cohort.
We retrospectively identified, from March 2008 to September 2014, 41 mCRC patients who received chemotherapy with cetuximab (9 received cetuximab in first, 26 in second and 6 in third line).
n informed consent, approved by for tissue collection and use for scientific purpose was obtained from each patient enrolled Genotyping of rs1801274 (A>G) in the FCGR2A, rs396991 (T>G) in FCGR3A and rs61764370 in the 3' UTR of KRAS genes was done on genomic DNA isolated from peripheral blood samples using a commercial kit (Qiagen, Germany) according to the manufacturer's instructions. Analyses were determined using appropriate the allelic discrimination assays from Life Technologies (Foster city, CA, US): c_9077561_20 for rs1801274; c_25815666_10 for rs396991 and 1350086 for rs61764370 using the ABIPRISM 7000 Sequence Detection System. Mutational analysis for KRAS (codons 12-13-59-61) gene was determined on patients' Formalin Fixed Paraffin Embedded (FFPE) tumor tissues archived at diagnosis in the Pathology Department of our Institution. KRAS gene analysis was performed by pyrosequencing using PyroMark ID System (Biotage, Uppsala, Sweden).
CD3+/CD56-and invNKT cells by co-expression of CD3, TCR V24, TCR V11. ADCC was evaluated over time as ex vivo NK-dependent activity Statistical analysis was performed using Prism software (version 5.0, GraphPad Software, La Jolla, CA).
KRAS mutational analysis in the 41 mCRC patients ( Table 1) showed 2 mutated samples (G12V and Q61H) in patients treated with cetuximab in first line (N=9), while the remaining patients treated in second (N=26) and third (N=6) line resulted wild-type.
The genotype distributions obtained for rs1801274 of FCGR2A, rs366991 of FCGR3A and rs61764370, located in the let-7 complementary site 6 (LCS6) of the KRAS 3' UTR, in the 41 mCRC patients of this study are presented in Table 2 .
Median ADCC activity at treatment start for all the 41 mCRC patients was 68.5% (range 10-99%). Correlation with OS and PFS was evaluated only in the sub-group of 26 patients treated with cetuximab in second line as it was the major group. Characteristics of the 26 patients treated in second line are described in Table 3 .
For this latter group of 26 patients treated with cetuximab in II line, median follow-up was 13 months (range 3-37) for OS and 5.5 months (range 2-37) for PFS, while the median value of ADCC was 71%. Patients performing ADCC activity above the median value showed an improved OS compared to patients with ADCC activity below this value (median 21 vs 12 months; P=0.045; Long-rank Mantel-Cox Test) (Figure 1) .
Correlation in terms of OS and PFS with genotypes of rs1801274 (A>G) in the FCGR2A, rs396991 (T>G) in FCGR3A and rs61764370 in the 3' UTR of KRAS genes resulted significant in PFS for SNP in FCGR2A (P=0.04). Patients carrying alleles with A presented a longer PFS in comparison with GG genotype (median 8 vs 3 months; p=0.04; Long-rank Mantel-Cox Test) (Figure 2) .
Moreover patients showing the TT genotype of SNP rs396991 in FCGR3A gene presented also a longer PFS in comparison with patients carrying allele G (GT or GG), although this difference was not significant (median 11 vs 5 months; p=0.053; Long-rank Mantel-Cox Test) (Figure 3 ).
Patients carring both the A allele (AA or AG) for SNP rs1801274 of FCGR2A gene and the TT genotype of FCGR3A gene performed better than all the other subgroups (median 11 vs 5 months; p=0.024; Long-rank Mantel-Cox Test) (Figure 4) .
These results indicate a link between ADCC activity, genotypes for FCGR2A and FCGR3A genes, coding FcRII and FcRIII, and efficacy of cetuximab in KRAS wild-type mCRC patients. This is in particular evident for patients treated with cetuximab in II line. Our results should be confirmed by further large prospective studies. This effect resulted even amplified when PFS was evaluated in FCGR2A favourable alleles stratified for FCGR3A.
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